An interventional study of GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter in Congenital Diaphragmatic Hernia and Pulmonary Hypoplasia, sponsored by Children's Hospital of Philadelphia. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Children's Hospital of Philadelphia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 16th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2015, is one of 28 with no phase, reaches primary completion later than 1 of the 27 other live ones, and was the 12th registered.
86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.
Browse Hernias, Diaphragmatic, Congenital studies →24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:
Mauro H. Schenone · Sites in United States
Ages 18–50 · Women only
Dr Erin Perrone · Sites in United States
Ages 18+
Vincent Duron · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 mo–1 mo
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is close to the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.
Median enrollment 21 across the 36 interventional studies, 51 across the 8 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
Children's Hospital of Philadelphia is the lead sponsor of 490 studies on the registry; 90 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 22 (79%) have results posted.
Children's Hospital of Philadelphia has 2 studies filed under Hernias, Diaphragmatic, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Hernias, Diaphragmatic, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04583644Hanmin LeePilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH) | 2027-04 |
| NCT00950118Columbia UniversityDiaphragmatic Hernia Research & Exploration, Advancing Molecular Science | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CDH is a birth defect characterized by the development, very early in gestation, of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, the intestines and other organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally.
In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so these children are capable of surviving and thriving.
Study Summary
All patients will complete a standard prenatal evaluation at the Center for Fetal Diagnosis and Treatment (CFDT) to find out if they are candidates. The standard clinical assessments include: Medical history and Physical exam, Level II ultrasound, Fetal echocardiogram, Fetal magnetic resonance imaging (MRI), and a Psychosocial assessment.
If determined eligible, patients will be extensively counseled by the CFDT Team and those who choose to participate will provide written, informed consent for study enrollment.
Up to 25 women will be enrolled in the FETO study. The mother and her unborn baby will undergo two procedures. A balloon will be placed in the unborn baby's airway between 27+0/7 - 29+6/7 gestational age. The balloon blocks the airway and remains in place until balloon removal. The timing for balloon removal will be determined by the CFDT Management Team and can occur between 34 +0/7 - 34+6/7 gestational age.
Mothers enrolled in this study must remain near the fetal center, under close supervision, from the time of balloon placement through delivery in the Garbose Family Special Delivery Unit.
Weekly prenatal monitoring will occur after the first procedure at the CFDT and planned delivery will occur in the Garbose Family Special Delivery Unit at term.
Postnatal stabilization and subsequent surgery to repair the diaphragm will take place at CHOP.
Infants will be followed at CHOP at 6 months, 12 months, and 2 years of age and then long-term in the Pulmonary Hypoplasia Program at The Children's Hospital of Philadelphia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Singleton pregnancy
Fetal:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Device: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Successful Balloon Placement and Removal.
Successful balloon placement and removal will be counted per patient. FETO insertion will be attempted up to 3 times in a single pregnant woman/ fetus. The maximum duration of balloon implantation, if placed at 27 weeks 0 days and removed in the 34th week, is 7 weeks. For those balloons placed later in gestation or removed earlier electively or emergently, the duration will be shorter.
Time frame: 7 weeks
Fetal Lung Growth Due to FETO
Fetal lung growth is assessed by O/E LHR measurement at time of balloon insertion (27w0d-29w6d) compared to O/E LHR measurement closest to 32w0d.
Time frame: 7 weeks
Survival Rate of FETO Patients
This outcome measures the survival rate of all 14 maternal and 14 neonatal subjects until the end of the follow-up period (24 months corrected age, +/- one month)
Time frame: Enrollment to end of the follow-up period (24 months corrected age, +/- one month)
All patients referred to the CHOP Center for Fetal Diagnosis and Treatment (CFDT) with a confirmed diagnosis of CDH were screened for eligibility criteria.
| Milestone | FETO in CDH - Maternal | FETO in CDH - Fetal/Neonatal |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 13 |
| Not completed | 0 | 1 |
| Withdrew: Death | 0 | 1 |
Successful balloon placement and removal will be counted per patient. FETO insertion will be attempted up to 3 times in a single pregnant woman/ fetus. The maximum duration of balloon implantation, if placed at 27 weeks 0 days and removed in the 34th week, is 7 weeks. For those balloons placed later in gestation or removed earlier electively or emergently, the duration will be shorter.
| Participants | FETO in CDH |
|---|---|
| Number of cases in which balloon was successfully placed and removed by puncture or fetoscopy | 9 |
| Number of cases in which balloon was successfully placed and removed during C-section or EXIT | 5 |
Fetal lung growth is assessed by O/E LHR measurement at time of balloon insertion (27w0d-29w6d) compared to O/E LHR measurement closest to 32w0d.
| Participants | FETO in CDH |
|---|---|
| Lung growth was < 5% change in O/E LHR | 3 |
| Lung growth was 5-10% change in O/E LHR | 4 |
| Lung growth was 10-15% change in O/E LHR | 3 |
| Lung growth was 15-20% change in O/E LHR | 4 |
This outcome measures the survival rate of all 14 maternal and 14 neonatal subjects until the end of the follow-up period (24 months corrected age, +/- one month)
| Participants | FETO in CDH - Maternal | FETO in CDH - Fetal/Neonatal |
|---|---|---|
| Survival Rate of FETO Patients | 14 | 13 |
Collected over From enrollment until end of follow-up (24 months corrected age, +/- 1 month). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FETO in CDH | 1/28 (3.6%) | 28/28 (100%) | 13/28 (46.4%) |
| Event | FETO in CDH |
|---|---|
| Respiratory distress/failure (Neonatal)Respiratory, thoracic and mediastinal disorders | 14/28 |
| Pulmonary hypertension (Neonatal)Respiratory, thoracic and mediastinal disorders | 14/28 |
| Gastroesophageal reflux disease (Neonatal)Gastrointestinal disorders | 14/28 |
| Feeding difficulties (Neonatal)Gastrointestinal disorders | 14/28 |
| Tracheomegaly and/or tracheomalacia (Neonatal)Respiratory, thoracic and mediastinal disorders | 13/28 |
| Preterm premature rupture of membranesPregnancy, puerperium and perinatal conditions | 11/28 |
| Preterm delivery ( < 37 weeks GA)Pregnancy, puerperium and perinatal conditions | 11/28 |
| Preterm LaborPregnancy, puerperium and perinatal conditions | 10/28 |
| Premature birth with a weight of < 2500 gm (Neonatal)Pregnancy, puerperium and perinatal conditions | 10/28 |
| Chorioamniotic membrane separationPregnancy, puerperium and perinatal conditions | 7/28 |
| Event | FETO in CDH |
|---|---|
| Reactive airway disease (Neonatal)Respiratory, thoracic and mediastinal disorders | 6/28 |
| Grade 1 germinal matrix bleed (Neonatal)Nervous system disorders | 4/28 |
| Prenatal abdominal pain (Maternal)Pregnancy, puerperium and perinatal conditions | 2/28 |
| Vasovagal reaction to epidural placement (Maternal)Vascular disorders | 1/28 |
| Ileus (Maternal)Gastrointestinal disorders | 1/28 |
| Preeclampsia without severe features (Maternal)Pregnancy, puerperium and perinatal conditions | 1/28 |
| Age, Customized(Participants) | FETO in CDH |
|---|---|
| Number of maternal participants ≥ 18 years of age | 14 |
| Age Not Collected (Neonates Only) | 0 |
| Sex: Female, Male(Participants) | FETO in CDH |
|---|---|
| Sex of maternal participants — Female | 14 |
| Sex of maternal participants — Male | 0 |
| Sex of fetal/neonatal participants — Female | 6 |
| Sex of fetal/neonatal participants — Male | 8 |
| Race (NIH/OMB)(Participants) | FETO in CDH |
|---|---|
| Race of maternal participants — American Indian or Alaska Native | 0 |
| Race of maternal participants — Asian | 0 |
| Race of maternal participants — Native Hawaiian or Other Pacific Islander | 0 |
| Race of maternal participants — Black or African American | 1 |
| Race of maternal participants — White | 12 |
| Race of maternal participants — More than one race | 1 |
| Race of maternal participants — Unknown or Not Reported | 0 |
| Race of fetal/neonatal participants — American Indian or Alaska Native | 0 |
| Race of fetal/neonatal participants — Asian | 0 |
| Race of fetal/neonatal participants — Native Hawaiian or Other Pacific Islander | 0 |
| Race of fetal/neonatal participants — Black or African American | 1 |
| Race of fetal/neonatal participants — White | 12 |
| Race of fetal/neonatal participants — More than one race | 1 |
| Race of fetal/neonatal participants — Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | FETO in CDH |
|---|---|
| Ethnicity of maternal participants — Hispanic or Latino | 1 |
| Ethnicity of maternal participants — Not Hispanic or Latino | 13 |
| Ethnicity of maternal participants — Unknown or Not Reported | 0 |
| Ethnicity of fetal/neonatal participants — Hispanic or Latino | 2 |
| Ethnicity of fetal/neonatal participants — Not Hispanic or Latino | 12 |
| Ethnicity of fetal/neonatal participants — Unknown or Not Reported | 0 |
| Maternal BMI(Participants) | FETO in CDH |
|---|---|
| BMI 20-25 | 1 |
| BMI 25-30 | 7 |
| BMI 30-35 | 3 |
| BMI 35-40 | 1 |
| BMI 40-45 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jul 2015, a primary completion of May 2025 and a completion of Jul 2027. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2026, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hernias, Diaphragmatic, Congenital →
Children's Hospital of Philadelphia →